

مستلزمات جراحة قلب

رقم المناقصة 87/2024/53 Sup

١-شركة SAAR /مكتب السار

Offer Ref: 57 /SR
Date:26/9/2024

1	2	3	4	5			6			
New National Code	Kimadia Description	Item code	Brief Description of Goods	Quantity Offered & Physical Unit	Country of Origin	CIP Price	DDP at End-User Site	Incidental Services as Defined in Schedule of Requirement	DDP at End-user, Site & Incidental Series	Total Price on DDP, Free Delivery at End User Site/USD
CRS-DE00-035	Composit graft cardiac aortic valve size 31 with zero porosity dacron graft with valsalva	502AG31	AVG 502AG31 CONDUIT	17	USA	2,650.00	2,650.00		2,650.00	45,050.00
CRS-DE00-038	Aortic tissue valve size 21 mm	T505C221	VLV T505C221 HKII BIOPROS AOR 26L PEEK	85	USA	2,200.00	2,200.00		2,200.00	187,000.00
CRS-DE00-039	Aortic tissue valve size 23 mm	T505C223	VLV T505C223 HKII BIOPROS AOR 26L PEEK	43	USA	2,200.00	2,200.00		2,200.00	94,600.00
CRS-DE00-040	Aortic tissue valve size 25 mm	T505C225	VLV T505C225 HKII BIOPROS AOR 26L PEEK	13	USA	2,200.00	2,200.00		2,200.00	28,600.00
CRS-DE00-048	Mitral tissue valves size 27mm	T510C27	VLV T510C27 HKII BIOPROS MIT 26L PEEK	84	USA	2,200.00	2,200.00		2,200.00	184,800.00
CRS-DE00-049	Mitral tissue valves size 29mm	T510C29	VLV T510C29 HKII BIOPROS MIT 26L PEEK	86	USA	2,200.00	2,200.00		2,200.00	189,200.00
Grand Total of Bid Price in USD							\$729,250.00			
Grand Total of Bid Price in USD in Words							Seven Hundred Twenty Nine Thousand Two Hundred Fifty Dollars and No Cents			

٢-شركة DIYALA

Date: 26th September 2024

Commercial Proforma Invoice							
MOH product	Edwards Product Code	Edwards Product Description	Unit Package	QTY	Unit Price (USD)	Total Price (USD)	Shelf Life (years)
CRS-DE00-038	3300TFX21MM	Carpentier-Edwards Perimount MAGNA EASE AORTIC valve size 21mm	1 valve	85	2,000	170,000	4
CRS-DE00-039	3300TFX23MM	Carpentier-Edwards Perimount MAGNA EASE AORTIC valve size 23mm	1 valve	43	2,000	86,000	4
CRS-DE00-040	3300TFX25MM	Carpentier-Edwards Perimount MAGNA EASE AORTIC valve size 25mm	1 valve	13	2,000	26,000	4
CRS-DE00-048	7300TFX27	Carpentier-Edwards Perimount MAGNA EASE MITRAL valve size 27mm	1 valve	84	2,000	168,000	4
CRS-DE00-049	7300TFX29	Carpentier-Edwards Perimount MAGNA EASE MITRAL valve size 29mm	1 valve	86	2,000	172,000	4
Total Final Price (USD)		US\$622,000.00 Six Hundred and Twenty Two Thousand US Dollars only.					

(in millions, except par value)

	December 31,	
	2023	2022
ASSETS		
Current assets		
Cash and cash equivalents	\$ 1,144.0	\$ 769.0
Short-term investments (Note 7)	500.5	446.3
Accounts receivable, net of allowances of \$8.3 and \$7.9, respectively	775.1	643.0
Other receivables	61.8	56.1
Inventories (Note 5)	1,168.2	875.5
Prepaid expenses	146.8	110.0
Other current assets	239.3	195.9
Total current assets	4,035.7	3,095.8
Long-term investments (Note 7)	583.9	1,239.0
Property, plant, and equipment, net (Note 5)	1,749.4	1,632.8
Operating lease right-of-use assets (Note 6)	94.0	92.3
Goodwill (Note 10)	1,253.5	1,164.3
Other intangible assets, net (Note 10)	428.4	285.2
Deferred income taxes	754.6	484.0
Other assets	463.7	299.1
Total assets	\$ 9,363.2	\$ 8,292.5
LIABILITIES AND STOCKHOLDERS' EQUITY		
Current liabilities		
Accounts payable	\$ 201.4	\$ 201.9
Accrued and other liabilities (Note 5)	969.1	795.0
Operating lease liabilities (Note 6)	24.9	25.5
Total current liabilities	1,195.4	1,022.4
Long-term debt (Note 11)	597.0	596.3
Contingent consideration liabilities (Note 12)	—	26.2
Taxes payable (Note 18)	80.6	143.4
Operating lease liabilities (Note 6)	73.0	69.5
Uncertain tax positions (Note 18)	339.3	267.5
Litigation settlement accrual (Note 3)	94.2	143.0
Other liabilities	264.3	217.5
Total liabilities	2,643.8	2,485.8
Commitments and contingencies (Notes 6, 11, and 19)		
Stockholders' equity (Note 15)		
Preferred stock, \$0.01 par value, authorized 50.0 shares, no shares outstanding	—	—
Common stock, \$1.00 par value, 1,050.0 shares authorized, 650.5 and 646.3 shares issued, and 601.1 and 608.3 shares outstanding, respectively	650.5	646.3
Additional paid-in capital	2,274.4	1,969.3
Retained earnings	8,992.4	7,590.0
Accumulated other comprehensive loss (Note 16)	(242.8)	(254.9)
Treasury stock, at cost, 49.4 and 38.0 shares, respectively	(5,024.5)	(4,144.0)
Total Edwards Lifesciences Corporation stockholders' equity	6,650.0	5,806.7
Noncontrolling interest (Note 9)	69.4	—
Total stockholders' equity	6,719.4	5,806.7
Total liabilities and stockholders' equity	\$ 9,363.2	\$ 8,292.5

The accompanying notes are an integral part of these consolidated financial statements.

	Years Ended December 31,		
	2023	2022	2021
Net sales	\$ 6,004.8	\$ 5,382.4	\$ 5,232.5
Cost of sales	1,379.8	1,080.4	1,248.9
Gross profit	4,625.0	4,302.0	3,983.6
Selling, general, and administrative expenses	1,824.6	1,567.6	1,493.7
Research and development expenses	1,071.8	945.2	903.1
Intellectual property agreement and litigation expense (Note 3)	203.5	15.8	20.6
Change in fair value of contingent consideration liabilities (Note 12)	(26.2)	(35.8)	(124.1)
Special charge and separation costs (Note 4)	17.2	60.7	—
Operating income	1,534.1	1,748.5	1,690.3
Interest expense	17.6	19.2	18.4
Interest income	(67.2)	(35.5)	(17.4)
Other income, net (Note 17)	(14.4)	(2.6)	(12.7)
Income before provision for income taxes	1,598.1	1,767.4	1,702.0
Provision for income taxes (Note 18)	198.7	245.5	198.9
Net income	1,399.4	1,521.9	1,503.1
Net loss attributable to noncontrolling interest (Note 9)	(3.0)	—	—
Net income attributable to Edwards Lifesciences Corporation.	\$ 1,402.4	\$ 1,521.9	\$ 1,503.1
Share information (Note 2):			
Earnings per share attributable to Edwards Lifesciences Corporation:			
Basic	\$ 2.31	\$ 2.46	\$ 2.41
Diluted	\$ 2.30	\$ 2.44	\$ 2.38
Weighted-average number of common shares outstanding attributable to Edwards Lifesciences Corporation:			
Basic	606.7	619.0	623.3
Diluted	609.4	624.2	631.2

The accompanying notes are an integral part of these consolidated financial statements.

	Years Ended December 31,		
	2023	2022	2021
Net income	\$ 1,399.4	\$ 1,521.9	\$ 1,503.1
Other comprehensive income (loss), net of tax (Note 16):			
Foreign currency translation adjustments	4.3	(46.3)	(50.1)
Unrealized (loss) gain on hedges	(23.1)	(5.9)	57.4
Unrealized pension (costs) credits	(9.9)	13.7	11.6
Unrealized gain (loss) on available-for-sale investments	40.8	(58.7)	(15.5)
Other comprehensive income (loss), net of tax	12.1	(97.2)	3.4
Comprehensive income	1,411.5	1,424.7	1,506.5
Comprehensive loss attributable to noncontrolling interest	(3.0)	—	—
Comprehensive income attributable to Edwards Lifesciences Corporation	\$ 1,414.5	\$ 1,424.7	\$ 1,506.5

The accompanying notes are an integral part of these consolidated financial statements.

	Common Stock		Treasury Stock		Additional Paid-in Capital	Retained Earnings	Accumulated Other Comprehensive Loss	Total Edwards Lifesciences Corporation Stockholders' Equity	Noncontrolling Interest	Total Stockholders' Equity
	Shares	Par Value	Shares	Amount						
BALANCE AT DECEMBER 31, 2020	636.4	\$ 636.4	12.1	\$ (1,904.1)	\$ 1,438.1	\$ 4,565.0	\$ (161.1)	\$ 4,574.3	\$ —	\$ 4,574.3
Net income						1,503.1		1,503.1		1,503.1
Other comprehensive loss, net of tax							3.4	3.4		3.4
Common stock issued under equity plans	5.6	5.6			153.0			158.6		158.6
Stock-based compensation expense					109.3			109.3		109.3
Purchases of treasury stock			5.8	(512.8)				(512.8)		(512.8)
BALANCE AT DECEMBER 31, 2021	642.0	642.0	17.9	(2,416.9)	1,700.4	6,068.1	(157.7)	5,835.9	—	5,835.9
Net income						1,521.9		1,521.9		1,521.9
Other comprehensive income, net of tax							(97.2)	(97.2)		(97.2)
Common stock issued under equity plans	4.3	4.3			142.1			146.4		146.4
Stock-based compensation expense					126.8			126.8		126.8
Purchases of treasury stock			20.1	(1,727.1)				(1,727.1)		(1,727.1)
BALANCE AT DECEMBER 31, 2022	646.3	646.3	38.0	(4,144.0)	1,969.3	7,590.0	(254.9)	5,806.7	—	5,806.7
Net income (loss)						1,402.4		1,402.4	(3.0)	1,399.4
Other comprehensive loss, net of tax							12.1	12.1		12.1
Common stock issued under equity plans	4.2	4.2			165.7			169.9		169.9
Stock-based compensation expense					139.4			139.4		139.4
Purchases of treasury stock			11.4	(880.5)				(880.5)		(880.5)
Changes to noncontrolling interest (Note 9)								—	72.4	72.4
BALANCE AT DECEMBER 31, 2023	650.5	650.5	49.4	(5,024.5)	2,274.4	8,992.4	(242.8)	6,650.0	69.4	6,719.4

The accompanying notes are an integral part of these consolidated financial statements.

	Years Ended December 31,		
	2023	2022	2021
Net income	\$ 1,399.4	\$ 1,521.9	\$ 1,503.1
Other comprehensive income (loss), net of tax (Note 16):			
Foreign currency translation adjustments	4.3	(46.3)	(50.1)
Unrealized (loss) gain on hedges	(23.1)	(5.9)	57.4
Unrealized pension (costs) credits	(9.9)	13.7	11.6
Unrealized gain (loss) on available-for-sale investments	40.8	(58.7)	(15.5)
Other comprehensive income (loss), net of tax	12.1	(97.2)	3.4
Comprehensive income	1,411.5	1,424.7	1,506.5
Comprehensive loss attributable to noncontrolling interest	(3.0)	—	—
Comprehensive income attributable to Edwards Lifesciences Corporation	\$ 1,414.5	\$ 1,424.7	\$ 1,506.5

The accompanying notes are an integral part of these consolidated financial statements.

	Years Ended December 31,		
	2023	2022	2021
Cash flows from operating activities			
Net income	\$ 1,399.4	\$ 1,521.9	\$ 1,503.1
Adjustments to reconcile net income to net cash provided by operating activities:			
Depreciation and amortization	144.9	139.6	134.8
Non-cash operating lease cost	28.2	27.2	28.5
Stock-based compensation (Notes 2 and 15)	139.4	126.8	109.3
Impairment charges (Note 4)	—	55.1	4.0
Change in fair value of contingent consideration liabilities (Note 12)	(26.2)	(35.8)	(124.1)
Loss (gain) on investments, net	0.1	51.5	(36.8)
Deferred income taxes	(272.1)	(254.5)	(41.4)
Other	8.4	7.8	9.4
Changes in operating assets and liabilities:			
Accounts and other receivables, net	(141.2)	(84.1)	(91.1)
Inventories	(289.0)	(213.4)	19.0
Prepaid expenses and other current assets	(81.8)	0.1	7.9
Accounts payable and accrued liabilities	146.0	(21.4)	195.2
Intellectual property agreement accrual	(33.0)	(45.0)	(29.2)
Income taxes	(5.8)	(5.6)	62.0
Long-term prepaid royalties (Note 3)	(109.9)	—	—
Other	(11.6)	(52.0)	(18.5)
Net cash provided by operating activities	895.8	1,218.2	1,732.1
Cash flows from investing activities			
Capital expenditures	(253.0)	(244.6)	(325.8)
Purchases of held-to-maturity investments (Note 7)	(66.4)	(353.5)	(250.0)
Proceeds from sales and maturities of held-to-maturity investments (Note 7)	97.9	419.5	138.0
Purchases of available-for-sale investments (Note 7)	(9.1)	(315.8)	(1,629.3)
Proceeds from sales and maturities of available-for-sale investments (Note 7)	617.9	939.6	391.2
Business combination, net of cash (Note 9)	(95.2)	—	—
Payments for acquisition options (Note 8)	(30.0)	(109.6)	(13.1)
Issuances of notes receivable	(62.5)	(52.3)	(5.1)
Collections of notes receivable	—	18.0	20.0
Investments in intangible assets	(13.3)	(20.2)	(4.0)
Other	(12.5)	(28.8)	(44.4)
Net cash provided by (used in) investing activities	173.8	252.3	(1,722.5)
Cash flows from financing activities			
Proceeds from issuance of debt	—	—	5.2
Payments on debt and finance lease obligations	(0.3)	(0.2)	(7.0)
Purchases of treasury stock	(879.6)	(1,727.1)	(512.8)
Proceeds from stock plans	169.9	146.4	158.6
Other	(1.0)	(3.6)	(0.3)
Net cash used in financing activities	(711.0)	(1,584.5)	(356.3)
Effect of currency exchange rate changes on cash, cash equivalents, and restricted cash	16.8	19.2	13.9
Net increase (decrease) in cash, cash equivalents, and restricted cash	375.4	(94.8)	(332.8)
Cash, cash equivalents, and restricted cash at beginning of year	772.6	867.4	1,200.2
Cash, cash equivalents, and restricted cash at end of year (Note 5)	\$ 1,148.0	\$ 772.6	\$ 867.4

The accompanying notes are an integral part of these consolidated financial statements.

	Shares	Par Value	Shares	Amount	Additional Paid-in Capital	Retained Earnings	Accumulated Other Comprehensive Loss	Total Edwards Lifesciences Corporation Stockholders' Equity	Noncontrolling Interest	Total Stockholders' Equity
BALANCE AT DECEMBER 31, 2020	636.4	\$ 636.4	12.1	\$ (1,904.1)	\$ 1,438.1	\$ 4,565.0	\$ (161.1)	\$ 4,574.3	\$ —	\$ 4,574.3
Net income						1,503.1		1,503.1		1,503.1
Other comprehensive loss, net of tax							3.4	3.4		3.4
Common stock issued under equity plans	5.6	5.6			153.0			158.6		158.6
Stock-based compensation expense					109.3			109.3		109.3
Purchases of treasury stock			5.8	(512.8)				(512.8)		(512.8)
BALANCE AT DECEMBER 31, 2021	642.0	642.0	17.9	(2,416.9)	1,700.4	6,068.1	(157.7)	5,835.9	—	5,835.9
Net income						1,521.9		1,521.9		1,521.9
Other comprehensive income, net of tax							(97.2)	(97.2)		(97.2)
Common stock issued under equity plans	4.3	4.3			142.1			146.4		146.4
Stock-based compensation expense					126.8			126.8		126.8
Purchases of treasury stock			20.1	(1,727.1)				(1,727.1)		(1,727.1)
BALANCE AT DECEMBER 31, 2022	646.3	646.3	38.0	(4,144.0)	1,969.3	7,590.0	(254.9)	5,806.7	—	5,806.7
Net income (loss)						1,402.4		1,402.4	(3.0)	1,399.4
Other comprehensive loss, net of tax							12.1	12.1		12.1
Common stock issued under equity plans	4.2	4.2			165.7			169.9		169.9
Stock-based compensation expense					139.4			139.4		139.4
Purchases of treasury stock			11.4	(880.5)				(880.5)		(880.5)
Changes to noncontrolling interest (Note 9)								—	72.4	72.4
BALANCE AT DECEMBER 31, 2023	650.5	650.5	49.4	(5,024.5)	2,274.4	8,992.4	(242.8)	6,650.0	69.4	6,719.4

The accompanying notes are an integral part of these consolidated financial statements.

	Years Ended December 31,		
	2022	2021	2020
Net income	\$ 1,521.9	\$ 1,503.1	\$ 823.4
Other comprehensive (loss) income, net of tax (Note 15):			
Foreign currency translation adjustments	(46.3)	(50.1)	32.4
Unrealized (loss) gain on hedges	(5.9)	57.4	(40.2)
Unrealized pension credits (costs)	13.7	11.6	(4.2)
Unrealized (loss) gain on available-for-sale investments	(77.5)	(24.1)	6.6
Reclassification of net realized investment loss to earnings	18.8	8.6	0.3
Other comprehensive (loss) income, net of tax	(97.2)	3.4	(5.1)
Comprehensive income	\$ 1,424.7	\$ 1,506.5	\$ 818.3

The accompanying notes are an integral part of these consolidated financial statements.

	Years Ended December 31,		
	2022	2021	2020
flows from operating activities			
Net income	\$ 1,521.9	\$ 1,503.1	\$ 823.4
Adjustments to reconcile net income to cash provided by operating activities:			
Depreciation and amortization	139.6	134.8	107.2
Non-cash operating lease cost	27.2	28.5	28.2
Stock-based compensation (Notes 2 and 14)	126.8	109.3	92.6
Impairment charges (Note 4)	55.1	4.0	—
Change in fair value of contingent consideration liabilities, net (Note 11)	(35.8)	(124.1)	13.6
Loss (gain) on investments, net	51.5	(36.8)	(21.2)
Deferred income taxes	(254.5)	(41.4)	(49.4)
Other	7.8	9.4	17.7
Changes in operating assets and liabilities:			
Accounts and other receivables, net	(84.1)	(91.1)	41.9
Inventories	(213.4)	19.0	(120.2)
Prepaid expenses and other current assets	0.1	7.9	(28.5)
Accounts payable and accrued liabilities	(21.4)	195.2	(84.5)
Litigation settlement accrual	(45.0)	(29.2)	270.5
Income taxes	(5.6)	62.0	(52.9)
Other	(52.0)	(18.5)	16.3
Net cash provided by operating activities	1,218.2	1,732.1	1,054.3
flows from investing activities			
Capital expenditures	(244.6)	(325.8)	(407.0)
Purchases of held-to-maturity investments (Note 7)	(353.5)	(250.0)	(162.0)
Proceeds from sales and maturities of held-to-maturity investments (Note 7)	419.5	138.0	212.2
Purchases of available-for-sale investments (Note 7)	(315.8)	(1,629.3)	(689.7)
Proceeds from sales and maturities of available-for-sale investments (Note 7)	939.6	391.2	564.8
Payment for acquisition option (Note 8)	(109.6)	(13.1)	(10.0)
Advances of notes receivable	(52.3)	(5.1)	(27.0)
Collections of notes receivable	18.0	20.0	—
Investments in intangible assets	(20.2)	(4.0)	(0.3)
Other	(28.8)	(44.4)	(12.1)
Net cash provided by (used in) investing activities	252.3	(1,722.5)	(531.1)
flows from financing activities			
Proceeds from issuance of debt	—	5.2	16.2
Payments on debt and finance lease obligations	(0.2)	(7.0)	(17.0)
Purchases of treasury stock	(1,727.1)	(512.8)	(625.4)
Proceeds from stock plans	146.4	158.6	140.5
Other	(3.6)	(0.3)	(1.2)
Net cash used in financing activities	(1,584.5)	(356.3)	(486.9)
Effect of currency exchange rate changes on cash, cash equivalents, and restricted cash	19.2	13.9	(20.5)
Net (decrease) increase in cash, cash equivalents, and restricted cash	(94.8)	(332.8)	15.8
Cash, cash equivalents, and restricted cash at beginning of year	867.4	1,200.2	1,184.4
Cash, cash equivalents, and restricted cash at end of year	\$ 772.6	\$ 867.4	\$ 1,200.2

The accompanying notes are an integral part of these consolidated financial statements.

	Years Ended December 31,		
	2022	2021	2020
Net sales	\$ 5,382.4	\$ 5,232.5	\$ 4,386.3
Cost of sales	1,080.4	1,248.9	1,080.6
Gross profit	4,302.0	3,983.6	3,305.7
Selling, general, and administrative expenses	1,567.6	1,493.7	1,228.4
Research and development expenses	945.2	903.1	760.7
Intellectual property litigation expenses, net (Note 3)	15.8	20.6	405.4
Change in fair value of contingent consideration liabilities, net (Note 11)	(35.8)	(124.1)	13.6
Special charge (Note 4)	60.7	—	—
Operating income	1,748.5	1,690.3	897.6
Interest expense	19.2	18.4	15.8
Interest income	(35.5)	(17.4)	(23.4)
Other income, net (Note 16)	(2.6)	(12.7)	(11.5)
Income before provision for income taxes	1,767.4	1,702.0	916.7
Provision for income taxes (Note 17)	245.5	198.9	93.3
Net income	\$ 1,521.9	\$ 1,503.1	\$ 823.4
Share information (Note 2):			
Earnings per share:			
Basic	\$ 2.46	\$ 2.41	\$ 1.32
Diluted	\$ 2.44	\$ 2.38	\$ 1.30
Weighted-average number of common shares outstanding:			
Basic	619.0	623.3	622.6
Diluted	624.2	631.2	631.9

The accompanying notes are an integral part of these consolidated financial statements.

	Years Ended December 31,		
	2022	2021	2020
Cash flows from operating activities			
Net income	\$ 1,521.9	\$ 1,503.1	\$ 823.4
Adjustments to reconcile net income to cash provided by operating activities:			
Depreciation and amortization	139.6	134.8	107.2
Non-cash operating lease cost	27.2	28.5	28.2
Stock-based compensation (Notes 2 and 14)	126.8	109.3	92.6
Impairment charges (Note 4)	55.1	4.0	—
Change in fair value of contingent consideration liabilities, net (Note 11)	(35.8)	(124.1)	13.6
Loss (gain) on investments, net	51.5	(36.8)	(21.2)
Deferred income taxes	(254.5)	(41.4)	(49.4)
Other	7.8	9.4	17.7
Changes in operating assets and liabilities:			
Accounts and other receivables, net	(84.1)	(91.1)	41.9
Inventories	(213.4)	19.0	(120.6)
Prepaid expenses and other current assets	0.1	7.9	(28.5)
Accounts payable and accrued liabilities	(21.4)	195.2	(84.5)
Litigation settlement accrual	(45.0)	(29.2)	270.5
Income taxes	(5.6)	62.0	(52.9)
Other	(52.0)	(18.5)	16.3
Net cash provided by operating activities	1,218.2	1,732.1	1,054.3
Cash flows from investing activities			
Capital expenditures	(244.6)	(325.8)	(407.0)
Purchases of held-to-maturity investments (Note 7)	(353.5)	(250.0)	(162.0)
Proceeds from sales and maturities of held-to-maturity investments (Note 7)	419.5	138.0	212.2
Purchases of available-for-sale investments (Note 7)	(315.8)	(1,629.3)	(689.7)
Proceeds from sales and maturities of available-for-sale investments (Note 7)	939.6	391.2	564.8
Payment for acquisition option (Note 8)	(109.6)	(13.1)	(10.0)
Issuances of notes receivable	(52.3)	(5.1)	(27.0)
Collections of notes receivable	18.0	20.0	—
Investments in intangible assets	(20.2)	(4.0)	(0.3)
Other	(28.8)	(44.4)	(12.1)
Net cash provided by (used in) investing activities	252.3	(1,722.5)	(531.1)
Cash flows from financing activities			
Proceeds from issuance of debt	—	5.2	16.2
Payments on debt and finance lease obligations	(0.2)	(7.0)	(17.0)
Purchases of treasury stock	(1,727.1)	(512.8)	(625.4)
Proceeds from stock plans	146.4	158.6	140.5
Other	(3.6)	(0.3)	(1.2)
Net cash used in financing activities	(1,584.5)	(356.3)	(486.9)
Effect of currency exchange rate changes on cash, cash equivalents, and restricted cash	19.2	13.9	(20.5)
Net (decrease) increase in cash, cash equivalents, and restricted cash	(94.8)	(332.8)	15.8
Cash, cash equivalents, and restricted cash at beginning of year	867.4	1,200.2	1,184.4
Cash, cash equivalents, and restricted cash at end of year	\$ 772.6	\$ 867.4	\$ 1,200.2

The accompanying notes are an integral part of these consolidated financial statements.

	years ended December 31,		
	2020	2019	2018
Net sales	\$ 4,386.3	\$ 4,348.0	\$ 3,722.8
Cost of sales	1,080.6	1,114.4	939.4
Gross profit	3,305.7	3,233.6	2,783.4
Selling, general, and administrative expenses	1,228.4	1,242.2	1,088.5
Research and development expenses	760.7	752.7	622.2
Intellectual property litigation expenses, net (Note 3)	405.4	33.4	214.0
Change in fair value of contingent consideration liabilities	13.6	(6.1)	(5.7)
Special charges (Note 4)	—	64.6	116.2
Operating income	897.6	1,146.8	748.2
Interest expense	15.8	20.7	29.9
Interest income	(23.4)	(32.2)	(32.0)
Special gain (Note 4)	—	—	(7.1)
Other income, net (Note 16)	(11.5)	(8.2)	(4.0)
Income before provision for income taxes	916.7	1,166.5	761.4
Provision for income taxes (Note 17)	93.3	119.6	39.2
Net income	\$ 823.4	\$ 1,046.9	\$ 722.2
Per share information (Note 2):			
Earnings per share:			
Basic	\$ 1.32	\$ 1.68	\$ 1.15
Diluted	\$ 1.30	\$ 1.64	\$ 1.13
Weighted-average number of common shares outstanding:			
Basic	622.6	624.8	627.6
Diluted	631.9	636.7	640.9

The accompanying notes are an integral part of these consolidated financial statements.

	Years Ended December 31,		
	2020	2019	2018
Net income	\$ 823.4	\$ 1,046.9	\$ 722.2
Comprehensive (loss) income, net of tax (Note 15):			
Foreign currency translation adjustments	32.4	(11.2)	(38.6)
Realized (loss) gain on hedges	(40.2)	(11.1)	40.4
Realized pension costs	(4.2)	(1.9)	0.6
Realized gain (loss) on available-for-sale investments	6.6	6.3	(3.3)
Classification of net realized investment loss to earnings	0.3	0.4	2.9
Comprehensive (loss) income, net of tax	(5.1)	(17.5)	2.0
Comprehensive income	\$ 818.3	\$ 1,029.4	\$ 724.2

The accompanying notes are an integral part of these consolidated financial statements.

	Years Ended December 31,		
	2020	2019	2018
Cash flows from operating activities			
Net income	\$ 823.4	\$ 1,046.9	\$ 722.2
Adjustments to reconcile net income to cash provided by operating activities:			
Depreciation and amortization	107.2	89.3	77.4
Non-cash operating lease cost	28.2	25.3	—
Stock-based compensation (Notes 2 and 14)	92.6	81.3	71.0
Inventory write off	—	73.1	—
Impairment charges (Note 4)	—	40.6	118.8
Change in fair value of contingent consideration liabilities, net (Note 11)	13.6	(6.1)	(5.7)
Deferred income taxes	(49.4)	12.1	(27.3)
Purchased in-process research and development	—	24.0	—
Other	(3.5)	(2.8)	13.0
Changes in operating assets and liabilities:			
Accounts and other receivables, net	41.9	(88.0)	(28.7)
Inventories	(120.6)	(105.4)	(65.7)
Prepaid expenses and other current assets	(28.5)	(6.8)	15.6
Accounts payable and accrued liabilities	(84.5)	116.5	12.5
Litigation settlement accrual	270.5	(180.0)	180.0
Income taxes	(52.9)	43.2	(157.8)
Other	16.3	19.7	1.4
Net cash provided by operating activities	1,054.3	1,182.9	926.7
Cash flows from investing activities			
Capital expenditures			
Purchases of held-to-maturity investments (Note 7)	(407.0)	(254.4)	(238.7)
Proceeds from sales and maturities of held-to-maturity investments (Note 7)	(162.0)	(130.2)	(210.0)
Purchases of available-for-sale investments (Note 7)	212.2	50.0	578.1
Proceeds from sales and maturities of available-for-sale investments (Note 7)	(689.7)	(437.9)	(249.3)
Acquisition (Notes 8 and 9)	564.8	359.9	223.2
Payment for acquisition option	—	(100.2)	—
Issuances of notes receivable	(10.0)	(35.0)	—
Investments in intangible assets and in-process research and development	(27.0)	(12.9)	(0.6)
Other	(0.3)	(24.0)	(3.0)
Net cash (used in) provided by investing activities	(531.1)	(595.8)	76.7
Cash flows from financing activities			
Proceeds from issuance of debt	16.2	18.9	688.0
Payments on debt and finance lease obligations	(17.0)	(28.9)	(1,125.3)
Purchases of treasury stock	(625.4)	(263.3)	(795.5)
Proceeds from stock plans	140.5	160.5	147.0
Payment of contingent consideration	—	—	(15.1)
Other	(1.2)	(2.8)	(0.3)
Net cash used in financing activities	(486.9)	(115.6)	(1,101.2)
Effect of currency exchange rate changes on cash, cash equivalents, and restricted cash	(20.5)	(3.0)	(6.5)
Net increase (decrease) in cash, cash equivalents, and restricted cash	15.8	468.5	(104.3)
Cash, cash equivalents, and restricted cash at beginning of year	1,184.4	715.9	820.2
Cash, cash equivalents, and restricted cash at end of year	\$ 1,200.2	\$ 1,184.4	\$ 715.9

The accompanying notes are an integral part of these consolidated financial statements.

	Common Stock		Treasury Stock		Additional Paid-in Capital	Retained Earnings	Accumulated Other Comprehensive Loss	Total Stockholders' Equity
	Shares	Par Value	Shares	Amount				
BALANCE AT DECEMBER 31, 2017	212.0	\$ 212.0	2.3	\$ (252.1)	\$ 1,166.9	\$ 1,962.1	\$ (132.7)	\$ 2,956.2
Impact to retained earnings from adoption of ASU 2016-16 and ASU 2018-02						10.4	(7.8)	2.6
BALANCE AT JANUARY 1, 2018	212.0	212.0	2.3	(252.1)	1,166.9	1,972.5	(140.5)	2,958.8
Net income						722.2		722.2
Other comprehensive income, net of tax							2.0	2.0
Common stock issued under equity plans	3.2	3.2			143.8			147.0
Stock-based compensation expense					71.0			71.0
Shares issued in payment for contingent consideration liabilities			(0.3)	32.2	2.7			34.9
Purchases of treasury stock			5.5	(795.5)				(795.5)
BALANCE AT DECEMBER 31, 2018	215.2	215.2	7.5	(1,015.4)	1,384.4	2,694.7	(138.5)	3,140.4
Net income						1,046.9		1,046.9
Other comprehensive loss, net of tax							(17.5)	(17.5)
Common stock issued under equity plans	2.9	2.9			157.6			160.5
Stock-based compensation expense					81.3			81.3
Purchases of treasury stock			1.5	(263.3)				(263.3)
BALANCE AT DECEMBER 31, 2019	218.1	218.1	9.0	(1,278.7)	1,623.3	3,741.6	(156.0)	4,148.3
Net income						823.4		823.4
Other comprehensive loss, net of tax							(5.1)	(5.1)
Common stock issued under equity plans	4.5	4.5			136.0			140.5
Stock-based compensation expense					92.6			92.6
Purchases of treasury stock			3.1	(625.4)				(625.4)
Stock issued to effect stock split	413.8	413.8			(413.8)			
BALANCE AT DECEMBER 31, 2020	636.4	\$ 636.4	12.1	\$ (1,904.1)	\$ 1,438.1	\$ 4,565.0	\$ (161.1)	\$ 4,574.3

The accompanying notes are an integral part of these consolidated financial statements.

٣-شركة انجازات / مكتب المجد

1		2		3	4	5				6	
National Code	Seller Code	Item No.	Brief Description of Goods		Quantity Offered & Physical Unit	Country of Origin	Price per Physical Unit in USD				Total Price on DDP, Free Delivery at End User Site/USD
			Product	Unit Pack Size			CIP Price	DDP at End-User Site	Incidental Services as Defined in Schedule of Requirement	DDP at End-user, Site & Incidental Series	
CRS-DE00-035	31CAVGJ-514 00	1	Masters™ Valved Graft wt Hemashield™ Technology, 31mm	Pcs	17	USA	2,700.00	2,700.00	-	2,700.00	45,900.00
CRS-DE00-038	E200-21A	2	Epic™ Plus Aortic Stented Tissue Valve size 21 mm	Pcs	85	Brazil	1,540.00	1,540.00	-	1,540.00	130,900.00
CRS-DE00-039	E200-23A	3	Epic™ Plus Aortic Stented Tissue Valve size 23 mm	Pcs	43	Brazil	1,540.00	1,540.00	-	1,540.00	66,220.00
CRS-DE00-040	E200-25A	4	Epic™ Plus Aortic Stented Tissue Valve size 25 mm	Pcs	13	Brazil	1,540.00	1,540.00	-	1,540.00	20,020.00
CRS-DE00-048	E200-27M	5	Epic™ Plus Mitral Stented Tissue Valve size 27 mm	Pcs	84	Brazil	1,540.00	1,540.00	-	1,540.00	129,360.00
CRS-DE00-049	E200-29M	6	Epic™ Plus Mitral Stented Tissue Valve size 29 mm	Pcs	86	Brazil	1,540.00	1,540.00	-	1,540.00	132,440.00
Grand Total of Bid Price in USD		524,840.00									
Grand Total of Bid Price in USD in Words		Five Hundred Twenty Four Thousand Eight Hundred Fourty Dollars and No Cents									

Ministry of Health
The State Company For Marketing Drugs
And Medical Appliances (Kimadia)
Baghdad-IRAQ

2024 / 53
Priced Schedule

Invitation # SUP 87/2024/53
Our Ref # : SUP 87/2024/53 - ABT

1		2		3	4	5				6	
National Code	Seller Code	Item No.	Brief Description of Goods		Quantity Offered & Physical Unit	Country of Origin	Price per Physical Unit in USD				Total Price on DDP, Free Delivery at End User Site/USD
			Product	Unit Pack Size			CIP Price	DDP at End-User Site	Incidental Services as Defined in Schedule of Requirement	DDP at End-user, Site & Incidental Series	
CRS-DE00-035	31CAVGJ-514 00	1	Masters™ Valved Graft wt Hemashield™ Technology, 31mm	Pcs	17	USA	2,700.00	2,700.00	-	2,700.00	45,900.00
CRS-DE00-038	E200-21A	2	Epic™ Plus Aortic Stented Tissue Valve size 21 mm	Pcs	85	Brazil	1,540.00	1,540.00	-	1,540.00	130,900.00
CRS-DE00-039	E200-23A	3	Epic™ Plus Aortic Stented Tissue Valve size 23 mm	Pcs	43	Brazil	1,540.00	1,540.00	-	1,540.00	66,220.00
CRS-DE00-040	E200-25A	4	Epic™ Plus Aortic Stented Tissue Valve size 25 mm	Pcs	13	Brazil	1,540.00	1,540.00	-	1,540.00	20,020.00
CRS-DE00-048	E200-27M	5	Epic™ Plus Mitral Stented Tissue Valve size 27 mm	Pcs	84	Brazil	1,540.00	1,540.00	-	1,540.00	129,360.00
CRS-DE00-049	E200-29M	6	Epic™ Plus Mitral Stented Tissue Valve size 29 mm	Pcs	86	Brazil	1,540.00	1,540.00	-	1,540.00	132,440.00

Grand Total of Bid Price in USD 524,840.00

Grand Total of Bid Price in USD in Words Five Hundred Twenty Four Thousand Eight Hundred Fourty Dollars and No Cents

Delivery Period: 4-6 Months as per INCOTERMS current Edition
 Agent Name & address: Please Insert full details
 Agent Com N/A N/A
 Bidder: Al-Injazat Trading L.L.Co.
 Place:
 Date:

Signature of: Name & Designation
 Business Address
 Seal of the Bidder

Ministry of Health
The State Company For Marketing Drugs
And Medical Appliances (Kimadia)
Baghdad-IRAQ

Priced Schedule

Invitation # SUP 87/2024/53
Our Ref # : SUP 87/2024/53 - ABT

1		2			3	4	5				6	
National Code	Seller Code	Item No.	Brief Description of Goods		Unit Pack Size	Quantity Offered & Physical Unit	Country of Origin	Price per Physical Unit in USD				Total Price on DDP, Free Delivery at End User Site/USD
			Product					CIP Price	DDP at End-User Site	Incidental Services as Defined in Schedule of Requirement	DDP at End-user, Site & Incidental Series	
CRS-DE00-035	31CAVGJ-514 00	1	Masters™ Valved Graft wt Hemashield™ Technology, 31mm		Pcs	17	USA	2,700.00	2,700.00	-	2,700.00	45,900.00
CRS-DE00-038	E200-21A	2	Epic™ Plus Aortic Stented Tissue Valve size 21 mm		Pcs	85	Brazil	1,540.00	1,540.00	-	1,540.00	130,900.00
CRS-DE00-039	E200-23A	3	Epic™ Plus Aortic Stented Tissue Valve size 23 mm		Pcs	43	Brazil	1,540.00	1,540.00	-	1,540.00	66,220.00
CRS-DE00-040	E200-25A	4	Epic™ Plus Aortic Stented Tissue Valve size 25 mm		Pcs	13	Brazil	1,540.00	1,540.00	-	1,540.00	20,020.00
CRS-DE00-048	E200-27M	5	Epic™ Plus Mitral Stented Tissue Valve size 27 mm		Pcs	84	Brazil	1,540.00	1,540.00	-	1,540.00	129,360.00
CRS-DE00-049	E200-29M	6	Epic™ Plus Mitral Stented Tissue Valve size 29 mm		Pcs	86	Brazil	1,540.00	1,540.00	-	1,540.00	132,440.00

Grand Total of Bid Price in USD 524,840.00

Grand Total of Bid Price in USD in Words Five Hundred Twenty Four Thousand Eight Hundred Fourty Dollars and No Cents